Forte Biosciences (FBRX) Notes Payables (2016 - 2020)

Forte Biosciences (FBRX) has 5 years of Notes Payables data on file, last reported at $5.0 million in Q1 2020.

• On a quarterly basis, Notes Payables rose 126.0% year-over-year to $5.0 million in Q1 2020; TTM through Mar 2020 was $5.0 million, a 126.0% increase from a year earlier, with the FY2019 full-year figure at $4.7 million, changed N/A from the prior year.
• Notes Payables for Q1 2020 stood at $5.0 million, up from $4.7 million in the prior quarter.
• Over the last five years, Notes Payables for FBRX reached as high as $27.8 million in Q3 2019 and fell as low as $2.2 million in Q1 2019.
• Historically, Notes Payables has averaged $7.9 million across 5 years, with a median of $7.2 million in 2016.
• Across the five-year window, Notes Payables plunged 69.39% in 2019 and jumped 126.0% in 2020, its largest moves.
• Year by year, Notes Payables stood at $7.2 million in 2016, then changed by 0.0% to $7.2 million in 2017, then changed by 0.0% to $7.2 million in 2018, then slumped by 34.11% to $4.7 million in 2019, then increased by 5.0% to $5.0 million in 2020.
• Per Business Quant data, the three most recent Notes Payables figures were $5.0 million in Q1 2020, $4.7 million in Q4 2019, and $27.8 million in Q3 2019.